These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

308 related articles for article (PubMed ID: 24021463)

  • 1. Identification of amides derived from 1H-pyrazolo[3,4-b]pyridine-5-carboxylic acid as potent inhibitors of human nicotinamide phosphoribosyltransferase (NAMPT).
    Zheng X; Bair KW; Bauer P; Baumeister T; Bowman KK; Buckmelter AJ; Caligiuri M; Clodfelter KH; Feng Y; Han B; Ho YC; Kley N; Li H; Liang X; Liederer BM; Lin J; Ly J; O'Brien T; Oeh J; Oh A; Reynolds DJ; Sampath D; Sharma G; Skelton N; Smith CC; Tremayne J; Wang L; Wang W; Wang Z; Wu H; Wu J; Xiao Y; Yang G; Yuen PW; Zak M; Dragovich PS
    Bioorg Med Chem Lett; 2013 Oct; 23(20):5488-97. PubMed ID: 24021463
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fragment-based identification of amides derived from trans-2-(pyridin-3-yl)cyclopropanecarboxylic acid as potent inhibitors of human nicotinamide phosphoribosyltransferase (NAMPT).
    Giannetti AM; Zheng X; Skelton NJ; Wang W; Bravo BJ; Bair KW; Baumeister T; Cheng E; Crocker L; Feng Y; Gunzner-Toste J; Ho YC; Hua R; Liederer BM; Liu Y; Ma X; O'Brien T; Oeh J; Sampath D; Shen Y; Wang C; Wang L; Wu H; Xiao Y; Yuen PW; Zak M; Zhao G; Zhao Q; Dragovich PS
    J Med Chem; 2014 Feb; 57(3):770-92. PubMed ID: 24405419
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of 2,3-dihydro-1H-pyrrolo[3,4-c]pyridine-derived ureas as potent inhibitors of human nicotinamide phosphoribosyltransferase (NAMPT).
    Dragovich PS; Bair KW; Baumeister T; Ho YC; Liederer BM; Liu X; Liu Y; O'Brien T; Oeh J; Sampath D; Skelton N; Wang L; Wang W; Wu H; Xiao Y; Yuen PW; Zak M; Zhang L; Zheng X
    Bioorg Med Chem Lett; 2013 Sep; 23(17):4875-85. PubMed ID: 23899614
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fragment-based design of 3-aminopyridine-derived amides as potent inhibitors of human nicotinamide phosphoribosyltransferase (NAMPT).
    Dragovich PS; Zhao G; Baumeister T; Bravo B; Giannetti AM; Ho YC; Hua R; Li G; Liang X; Ma X; O'Brien T; Oh A; Skelton NJ; Wang C; Wang W; Wang Y; Xiao Y; Yuen PW; Zak M; Zhao Q; Zheng X
    Bioorg Med Chem Lett; 2014 Feb; 24(3):954-62. PubMed ID: 24433859
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of potent and efficacious cyanoguanidine-containing nicotinamide phosphoribosyltransferase (Nampt) inhibitors.
    Zheng X; Baumeister T; Buckmelter AJ; Caligiuri M; Clodfelter KH; Han B; Ho YC; Kley N; Lin J; Reynolds DJ; Sharma G; Smith CC; Wang Z; Dragovich PS; Oh A; Wang W; Zak M; Wang Y; Yuen PW; Bair KW
    Bioorg Med Chem Lett; 2014 Jan; 24(1):337-43. PubMed ID: 24279990
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Retinal toxicity, in vivo and in vitro, associated with inhibition of nicotinamide phosphoribosyltransferase.
    Zabka TS; Singh J; Dhawan P; Liederer BM; Oeh J; Kauss MA; Xiao Y; Zak M; Lin T; McCray B; La N; Nguyen T; Beyer J; Farman C; Uppal H; Dragovich PS; O'Brien T; Sampath D; Misner DL
    Toxicol Sci; 2015 Mar; 144(1):163-72. PubMed ID: 25505128
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structural and biochemical analyses of the catalysis and potency impact of inhibitor phosphoribosylation by human nicotinamide phosphoribosyltransferase.
    Oh A; Ho YC; Zak M; Liu Y; Chen X; Yuen PW; Zheng X; Liu Y; Dragovich PS; Wang W
    Chembiochem; 2014 May; 15(8):1121-30. PubMed ID: 24797455
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of nicotinamide phosphoribosyltransferase (NAMPT) inhibitors with no evidence of CYP3A4 time-dependent inhibition and improved aqueous solubility.
    Zak M; Liederer BM; Sampath D; Yuen PW; Bair KW; Baumeister T; Buckmelter AJ; Clodfelter KH; Cheng E; Crocker L; Fu B; Han B; Li G; Ho YC; Lin J; Liu X; Ly J; O'Brien T; Reynolds DJ; Skelton N; Smith CC; Tay S; Wang W; Wang Z; Xiao Y; Zhang L; Zhao G; Zheng X; Dragovich PS
    Bioorg Med Chem Lett; 2015 Feb; 25(3):529-41. PubMed ID: 25556090
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structure-based discovery of novel amide-containing nicotinamide phosphoribosyltransferase (nampt) inhibitors.
    Zheng X; Bauer P; Baumeister T; Buckmelter AJ; Caligiuri M; Clodfelter KH; Han B; Ho YC; Kley N; Lin J; Reynolds DJ; Sharma G; Smith CC; Wang Z; Dragovich PS; Gunzner-Toste J; Liederer BM; Ly J; O'Brien T; Oh A; Wang L; Wang W; Xiao Y; Zak M; Zhao G; Yuen PW; Bair KW
    J Med Chem; 2013 Aug; 56(16):6413-33. PubMed ID: 23859118
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structure based design of nicotinamide phosphoribosyltransferase (NAMPT) inhibitors from a phenotypic screen.
    Palacios DS; Meredith E; Kawanami T; Adams C; Chen X; Darsigny V; Geno E; Palermo M; Baird D; Boynton G; Busby SA; George EL; Guy C; Hewett J; Tierney L; Thigale S; Weihofen W; Wang L; White N; Yin M; Argikar UA
    Bioorg Med Chem Lett; 2018 Feb; 28(3):365-370. PubMed ID: 29275937
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of benzothiophene amides as potent inhibitors of human nicotinamide phosphoribosyltransferase.
    Chen W; Dong G; He S; Xu T; Wang X; Liu N; Zhang W; Miao C; Sheng C
    Bioorg Med Chem Lett; 2016 Feb; 26(3):765-768. PubMed ID: 26755394
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SAR and characterization of non-substrate isoindoline urea inhibitors of nicotinamide phosphoribosyltransferase (NAMPT).
    Curtin ML; Heyman HR; Clark RF; Sorensen BK; Doherty GA; Hansen TM; Frey RR; Sarris KA; Aguirre AL; Shrestha A; Tu N; Woller K; Pliushchev MA; Sweis RF; Cheng M; Wilsbacher JL; Kovar PJ; Guo J; Cheng D; Longenecker KL; Raich D; Korepanova AV; Soni NB; Algire MA; Richardson PL; Marin VL; Badagnani I; Vasudevan A; Buchanan FG; Maag D; Chiang GG; Tse C; Michaelides MR
    Bioorg Med Chem Lett; 2017 Aug; 27(15):3317-3325. PubMed ID: 28610984
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structure-Based Design of Potent Nicotinamide Phosphoribosyltransferase Inhibitors with Promising in Vitro and in Vivo Antitumor Activities.
    Bai J; Liao C; Liu Y; Qin X; Chen J; Qiu Y; Qin D; Li Z; Tu ZC; Jiang S
    J Med Chem; 2016 Jun; 59(12):5766-79. PubMed ID: 27224875
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structure-based identification of ureas as novel nicotinamide phosphoribosyltransferase (Nampt) inhibitors.
    Zheng X; Bauer P; Baumeister T; Buckmelter AJ; Caligiuri M; Clodfelter KH; Han B; Ho YC; Kley N; Lin J; Reynolds DJ; Sharma G; Smith CC; Wang Z; Dragovich PS; Oh A; Wang W; Zak M; Gunzner-Toste J; Zhao G; Yuen PW; Bair KW
    J Med Chem; 2013 Jun; 56(12):4921-37. PubMed ID: 23617784
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nicotinamide phosphoribosyltransferase inhibitors, design, preparation, and structure-activity relationship.
    Christensen MK; Erichsen KD; Olesen UH; Tjørnelund J; Fristrup P; Thougaard A; Nielsen SJ; Sehested M; Jensen PB; Loza E; Kalvinsh I; Garten A; Kiess W; Björkling F
    J Med Chem; 2013 Nov; 56(22):9071-88. PubMed ID: 24164086
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Minimizing CYP2C9 Inhibition of Exposed-Pyridine NAMPT (Nicotinamide Phosphoribosyltransferase) Inhibitors.
    Zak M; Yuen PW; Liu X; Patel S; Sampath D; Oeh J; Liederer BM; Wang W; O'Brien T; Xiao Y; Skelton N; Hua R; Sodhi J; Wang Y; Zhang L; Zhao G; Zheng X; Ho YC; Bair KW; Dragovich PS
    J Med Chem; 2016 Sep; 59(18):8345-68. PubMed ID: 27541271
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of potent and efficacious urea-containing nicotinamide phosphoribosyltransferase (NAMPT) inhibitors with reduced CYP2C9 inhibition properties.
    Gunzner-Toste J; Zhao G; Bauer P; Baumeister T; Buckmelter AJ; Caligiuri M; Clodfelter KH; Fu B; Han B; Ho YC; Kley N; Liang X; Liederer BM; Lin J; Mukadam S; O'Brien T; Oh A; Reynolds DJ; Sharma G; Skelton N; Smith CC; Sodhi J; Wang W; Wang Z; Xiao Y; Yuen PW; Zak M; Zhang L; Zheng X; Bair KW; Dragovich PS
    Bioorg Med Chem Lett; 2013 Jun; 23(12):3531-8. PubMed ID: 23668988
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Supplementation of nicotinic acid with NAMPT inhibitors results in loss of in vivo efficacy in NAPRT1-deficient tumor models.
    O'Brien T; Oeh J; Xiao Y; Liang X; Vanderbilt A; Qin A; Yang L; Lee LB; Ly J; Cosino E; LaCap JA; Ogasawara A; Williams S; Nannini M; Liederer BM; Jackson P; Dragovich PS; Sampath D
    Neoplasia; 2013 Dec; 15(12):1314-29. PubMed ID: 24403854
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardiotoxicity Associated with Nicotinamide Phosphoribosyltransferase Inhibitors in Rodents and in Rat and Human-Derived Cells Lines.
    Misner DL; Kauss MA; Singh J; Uppal H; Bruening-Wright A; Liederer BM; Lin T; McCray B; La N; Nguyen T; Sampath D; Dragovich PS; O'Brien T; Zabka TS
    Cardiovasc Toxicol; 2017 Jul; 17(3):307-318. PubMed ID: 27783203
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dual-targeted NAMPT inhibitors as a progressive strategy for cancer therapy.
    Ozgencil F; Gunindi HB; Eren G
    Bioorg Chem; 2024 Aug; 149():107509. PubMed ID: 38824699
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.